In 2017, diabetes continued to pull in the profits for the key players in the metabolic disorders market, representing 66% of total metabolic sales.
The top five companies in the metabolic space mainly attribute their success to the sales of their anti-diabetic drugs. This is unsurprising as the number of US patients diagnosed with diabetes breached 32 million in 2017.
Go deeper with GlobalData
Novo Nordisk is currently the world leader in the diabetes market and will remain so for years to come. The company boasted sales of $13.7 million in 2017. Sanofi/Regeneron and Amgen will further strengthen their position in the metabolic disorders space with their expected blockbusters Praluent and Repatha, despite initial slow uptake in 2017.
Currently, 15 out of 20 top-selling drugs in the metabolic disorders space are anti-diabetics. With Sanofi’s Lantus and Merck & Co’s Januvia generating the most in sales in 2017, $5.1 and $3.7 billion, respectively. The majority of these top-selling anti-diabetics have already reached the peak of their sales, however, and are unlikely to continue to drive growth in the market. Instead, currently marketed drugs, Trulicity, Tresiba, Praluent, and Repatha are most likely to drive the growth of the metabolic disorders market in coming years.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
Novo Nordisk AS
Amgen Inc